Form 8-K - Current report:
SEC Accession No. 0001213900-14-004486
Filing Date
2014-06-25
Accepted
2014-06-25 08:38:49
Documents
6
Period of Report
2014-06-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k062514_actiniumpharma.htm 8-K 33677
2 UNDERWRITING AGREEMENT f8k062514ex1i_actiniumph.htm EX-1.1 219756
3 OPINION OF HISCOCK & BARCLAY, LLP. f8k062514ex5i_actiniumph.htm EX-5.1 7907
4 PRESS RELEASE f8k062514ex99i_actiniumph.htm EX-99.1 11868
5 logo.jpg GRAPHIC 7982
6 logo1.jpg GRAPHIC 7031
  Complete submission text file 0001213900-14-004486.txt   295339
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 14938762
SIC: 6770 Blank Checks